Endoscopy and Anesthesia Outcomes Associated with Glucagon-Like Peptide-1 Receptor Agonist use in Patients Undergoing Outpatient Upper Endoscopy.

Gastrointest Endosc

Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Division of Digestive Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH. Electronic address:

Published: January 2025

Background And Aims: Glucagon-like peptide-1 receptor agonists (GLP1RAs) can cause delayed gastric emptying, raising concern for retained gastric contents (RGCs) during endoscopy and adverse anesthesia events. We aimed to determine associations between GLP1RA and endoscopy and anesthesia outcomes.

Methods: This single-center retrospective cohort study examined patients prescribed GLP1RA who underwent outpatient endoscopy stratified by exposure at the time of endoscopy. The GLP1RA group had ≥6 weeks of exposure as confirmed by pharmacy dispensation reports. The control group were patients not on GLP1RA at the time of endoscopy (prescription never filled, discontinued ≥6 weeks prior, or started post-endoscopy). The outcomes were the presence of solid RGCs, aborted procedures or any adverse anesthesia events.

Results: 598 patients were included in the study with 360 on GLP1RA and 298 controls. Baseline characteristics including age, sex, chronic opiate use, gastroparesis and prior gastric surgery were similar, but diabetes mellitus was more prevalent in the GLP1RA group (68% vs. 57%, p=0.005). The odds of solid RGCs was significantly higher in the GLP1RA group in multivariate analysis (OR 3.80; 95% CI 1.57-9.21; p=0.003), but odds were not increased in patients undergoing concurrent colonoscopy. More patients in the GLP1RA group had procedures aborted (1.3% vs. 0%, p=0.021), but rates of hypoxia were similar (0.2% vs. 0.3%, p=0.341). There were no cases of pulmonary aspiration.

Conclusion: Patients on GLP1RAs have increased rates of solid RGCs during upper endoscopy, but not with concurrent colonoscopy, and higher rates of aborted procedures, but similar rates of adverse anesthesia events.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gie.2025.01.004DOI Listing

Publication Analysis

Top Keywords

glp1ra group
16
adverse anesthesia
12
solid rgcs
12
endoscopy
8
endoscopy anesthesia
8
glucagon-like peptide-1
8
peptide-1 receptor
8
patients undergoing
8
upper endoscopy
8
anesthesia events
8

Similar Publications

This study compared the efficacy and safety of glucogan-like peptide-1 receptor agonists (GLP1RAs) combined with metformin versus metformin alone in women with polycystic ovary syndrome (PCOS). A systematic search of "PubMed", "EMBASE", "Cochrane Library", and "Web of Science", "Google Scholar" was conducted up to September 2024. Studies were included if they were RCTs investigating the combination of GLP1RAs and metformin in women diagnosed with PCOS.

View Article and Find Full Text PDF

Metabolic and insulin-resistant diseases, such as type 2 diabetes mellitus (T2DM), have become major health issues worldwide. The prevalence of insulin resistance in the general population ranges from 15.5% to 44.

View Article and Find Full Text PDF

Rationale & Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve cardiac and kidney outcomes in patients with diabetes; however their efficacy in individuals with reduced estimated glomerular filtration rate (eGFR) is uncertain. This study evaluated the effects of GLP-1RAs on kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD).

Study Design: Systematic review and meta-analysis of randomized controlled trials (RCTs) reported through May 25, 2024.

View Article and Find Full Text PDF

Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have risen exponentially in usage and have been shown to exert neuroprotective and anti-inflammatory effects across multiple organ systems. This study investigates whether GLP-1RAs influence the risk for age-related ocular diseases.

Design: Retrospective cohort study.

View Article and Find Full Text PDF

Frailty is an increasingly recognised complication of diabetes in older people and should be taken into consideration in management plans, including the use of the new therapies of sodium glucose cotransporter-2 (SGLT-2) inhibitors and glucagon like peptide-1 receptor agonists (GLP-1RA). The frailty syndrome appears to span across a spectrum, from a sarcopenic obese phenotype at one end, characterised by obesity, insulin resistance, and prevalent cardiovascular risk factors, to an anorexic malnourished phenotype at the other end, characterised by significant weight loss, reduced insulin resistance, and less prevalent cardiovascular risk factors. Therefore, the use of the new therapies may not be suitable for every frail older individual with diabetes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!